NSE CIPLA · BSE 500087 · Biotechnology & Drugs · NIFTY 50

Cipla Share Price

Market closed · NSE price as of Tue 29 Sep
₹1,379.30 ▼ −₹4.43 · 0.32%
Day range · 29 Sep
₹1,378.00Low₹1,402.00High
52-week range
₹1,165.55Low · 2 Apr 2026₹1,672.20High · 23 Oct 2025

Cipla Overview

Where the price stands, how it has moved and how it sits against its averages.

Cipla shares last traded at ₹1,379.30 on the NSE, down 0.32% on the day. That is 17.5% below the 52-week high of ₹1,672.20 and 18.3% above the 52-week low of ₹1,165.55. The stock trades at 33.06× earnings, below the sector average of 33.72. Its market value is ₹1,11,428 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Tue 29 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −0.32%
1 Week▼ −0.35%
This month▼ −2.12%
3 Months▼ −5.14%
6 Months▲ +11.03%
This year▼ −8.73%
1 Year▼ −7.31%

Share price growth a year (CAGR): 3 years ▲ +5.2% · 5 years ▲ +7.3% · 10 years ▲ +8.5%

Against the market: 1 Month ▲ +3.84% · 3 Months ▲ +0.33% · 6 Months ▲ +11.75% · This year ▲ +7.22% · 1 Year ▲ +1.99%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 0 of 6

  1. 50-day average₹1,420.98 ▼ price 2.9% below
  2. 100-day average₹1,411.65 ▼ price 2.3% below
  3. 5-day average₹1,390.38 ▼ price 0.8% below
  4. 20-day average₹1,389.32 ▼ price 0.7% below
  5. 300-day average₹1,385.44 ▼ price 0.4% below
  6. 10-day average₹1,379.77 ▼ price 0.0% below
  7. Today's price₹1,379.30

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Cipla Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
28,163
Net profit₹ crore · losses below zero
5,273
3,879

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹28,163 Cr ▲ +2.2% ₹3,879 Cr 13.8% ₹48.00 ₹13.00
FY 2025 ₹27,548 Cr ▲ +6.9% ₹5,273 Cr 19.1% ₹65.24 ₹13.00
FY 2024 ₹25,774 Cr ▲ +13.3% ₹4,122 Cr 16.0% ₹51.05 ₹13.00
FY 2023 ₹22,753 Cr ▲ +4.5% ₹2,802 Cr 12.3% ₹34.69 ₹8.50
FY 2022 ₹21,763 Cr ▲ +13.6% ₹2,517 Cr 11.6% ₹31.17 ₹5.00
FY 2021 ₹19,160 Cr ▲ +11.8% ₹2,405 Cr 12.6% ₹29.79 ₹5.00
FY 2020 ₹17,132 Cr — ₹1,547 Cr 9.0% ₹19.16 ₹3.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
19%
81%
  • Total assets₹42,496 Cr
  • Total liabilities₹8,064 Cr
  • Shareholders' equity₹34,432 Cr
  • Total debt₹614 Cr
  • Cash & investments₹10,028 Cr
  • Current ratio3.44×
  • Revenue growth, 5 yr8.01% a year
  • EPS growth, 5 yr10.01% a year
  • Operating margin (TTM)13.27%
  • Net margin (TTM)11.88%

Cash flow — FY26

Operating activities
▲ ₹3,940 Cr
Investing activities
▼ −₹2,326 Cr
Financing activities
▼ −₹1,234 Cr
Free cash flow
▲ ₹861 Cr
Net change in cash
▲ ₹473 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue17,131.9919,159.5921,763.3422,753.1225,774.0927,547.6228,162.59
Cost of revenue6,936.818,328.649,560.759,314.249,957.2210,159.9210,868.88
Gross profit10,195.1810,830.9512,202.5913,438.8815,816.8717,387.7017,293.71
Operating expenses15,091.1915,960.0518,430.6019,047.0320,714.9821,391.0323,724.07
Operating income2,040.803,199.543,332.743,706.095,059.116,156.594,438.52
Depreciation1,097.311,000.57987.831,017.83939.10993.381,082.60
Profit before tax2,178.183,290.063,493.274,038.355,701.906,820.815,223.63
Tax631.20888.76933.801,202.861,546.591,529.761,353.84
Net profit1,546.522,404.872,516.752,801.914,121.555,272.523,879.23
EPS (₹)19.1629.7931.1734.6951.0565.2448.00
Dividend per share (₹)3.005.005.008.5013.0013.0013.00

Cipla vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Cipla This stock ₹1,379.30 ▼ −0.32% ₹1,11,428 Cr 33.06 3.24 14.47% 11.88% 0.94%
Sun Pharmaceutical Industries ₹1,860.00 ▲ +1.09% ₹4,46,266 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,475.00 ▼ −0.59% ₹2,51,531 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,915.15 ▲ +0.94% ₹1,86,950 Cr 72.73 19.22 23.00% 15.29% 0.80%
Zydus Lifesciences ₹1,195.20 ▼ −1.39% ₹1,19,222 Cr 21.19 4.24 17.90% 18.51% 0.09%
Lupin ₹2,060.00 ▼ −0.09% ₹94,197 Cr 19.12 4.98 12.70% 19.16% 0.74%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Cipla shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
29.2%
20.2%
20.6%
30.0%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter29.21%29.21%29.21%29.21% 0.00 pts
FII24.54%23.93%22.55%20.20% ▼ −2.35 pts
MF20.23%19.21%18.66%20.56% ▲ +1.90 pts
Other26.02%27.65%29.58%30.03% ▲ +0.45 pts

Cipla Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

CiplaBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
33.06
▼ 2% below the sector average of 33.72
P/E, 12-month rangeLow 22.06 · high 35.14
84%
Today's P/E sits 84% of the way from its low to its high
P/BPrice ÷ book value per share
3.24
P/SMarket cap ÷ last 12 months' revenue
3.93
P/CFPrice ÷ cash flow per share
24.85
PEGP/E ÷ earnings growth rate
2.90

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
64.53%
▲ above its 5-yr average of 60.43%
Operating marginKept after running costs
13.27%
▼ below its 5-yr average of 18.01%
Pre-tax marginKept before tax
16.01%
▼ below its 5-yr average of 20.06%
Net marginKept as profit
11.88%
▼ below its 5-yr average of 14.85%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
11.82%
▼ below its 5-yr average of 14.47%
Return on assetsProfit on everything it owns
9.69%
▼ below its 5-yr average of 11.66%
Return on investmentProfit on long-term capital
11.52%
▼ below its 5-yr average of 14.07%
Return on capital employedProfit before interest and tax on equity + debt
15.67%

Growth Is the business getting bigger?

Revenue — last 12 months
+1.9%
▲ growing
Revenue — 3 yr, a year
+7.4%
▲ growing
Revenue — 5 yr, a year
+8.0%
▲ growing
Net profit — 3 yr, a year
+11.5%
▲ growing
Net profit — 5 yr, a year
+10.0%
▲ growing
EPS — last 12 months
−37.5%
▼ shrinking (off the scale)
EPS — 3 yr, a year
+11.4%
▲ growing
EPS — 5 yr, a year
+10.0%
▲ growing
Dividend — 3 yr, a year
+15.2%
▲ growing
Book value — 5 yr, a year
+13.4%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.02×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
3.44×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
2.48×
✓ Comfortable
Interest coverOperating profit ÷ interest to pay
71.06×
✓ Strong
Payout ratioShare of profit paid as dividend
27.08%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹41.70
Book value
₹426.24
Cash flow
₹55.66
Dividend
₹13.00
Revenue
₹350.44

The share price is 3.24× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 109 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year28.83
Current Dividend Yield - Common Stock Primary Issue, LTM0.94
Price to Book - most recent fiscal year3.25
P/E Basic excluding extraordinary items - TTM35.11
P/E including extraordinary items - TTM33.18
P/E excluding extraordinary items low, trailing 12 months22.06
Price to Tangible Book - most fiscal year4.05
Dividend Yield - 5 Year Average0.86
Price to sales - most recent fiscal year3.97
Dividend Yield - indicated annual dividend divided by closing price0.94
Price to Cash Flow per share - trailing 12 month24.85
Peg Ratio2.90
P/E Normalized, most recent fiscal year26.89
P/E excluding extraordinary items high, trailing 12 months35.14
P/E excluding extraordinary items, most recent fiscal year quarter33.18
Price to sales - trailing 12 month3.95
Net Debt, LFY−94,143.50

Per share

Dividend Per Share - 5 year average10.50
Cash Flow per share - trailing 12 month55.66
Cash Flow per share - most recent fiscal year61.27
EPS including extraordinary items - trailing 12 month41.70
EPS including extraordinary items - most recent fiscal year48.00
EBITD per share - trailing 12 month64.47
Revenue/share - trailing 12 month350.44
EPS excluding extraordinary items - trailing 12 month41.70
EPS Basic excluding extraordinary items - most recent fiscal year48.03
EPS Basic excluding extraordinary items - trailing 12 month41.74
Book value per share - most recent fiscal year426.25
Dividend per share - most recent fiscal year13.00
Revenue/share - most recent fiscal year348.44
EPS Normalized - most recent fiscal year51.46
Book value (tangible) per share - most recent fiscal year341.45
Dividends per share - trailing 12 month13.00
EPS excluding extraordinary items - most recent fiscal year48.00
Cash per share - most recent fiscal year124.14

Margins

Operating margin - trailing 12 month13.27
Gross Margin - 5 year average60.43
Operating margin - 1st historical fiscal year15.76
Operating Margin - 5 year average18.01
Net Profit Margin % - 1st historical fiscal year13.74
Gross Margin - 1st historical fiscal year61.41
Net Profit Margin % - trailing 12 month11.88
Net Profit Margin - 5 year average14.85
Pretax Margin - 5 year average20.06
Pretax margin - 1st historical fiscal year18.55
Pretax margin - trailing 12 month16.01
Free Operating Cash Flow/Revenue, 5 Year Average6.31
Gross Margin - trailing 12 month64.53

Growth

EPS Change %, TTM over TTM−37.50
Revenue growth rate, 5 year8.01
EPS growth rate, 5 year10.01
Revenue Change % - most recent quarter 1 year ago2.33
Growth rate% - dividend, 3 year15.21
Growth rate% - EPS, 3 year11.43
Revenue/share (5 yr growth)7.98
Tangible Book Value, Total Equity, 5 Year CAGR15.38
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR2.75
Capital Spending growth rate, 5 year30.33
Revenue Change %, TTM over TTM1.85
Growth rate% - Revenue, 3 year7.37
Book value per share growth rate, 5 year13.41
EPS Change % - most recent quarter 1 year ago−39.23
Net Profit Margin growth rate, 5 year1.86
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR6.81
Total Debt, 5 Year CAGR−21.16

Financial strength

Free Cash Flow - most recent fiscal year−4,316.90
LT debt/equity - most recent fiscal year0.01
Quick ratio - most recent fiscal year2.48
Payout ratio - trailing 12 month31.15
Current ratio - most recent fiscal year3.44
Current EV/Free Cash Flow, LFY176.45
Total debt/total equity - most recent fiscal year0.02
Net Interest coverage - trailing 12 month71.06
Payout ratio - most recent fiscal year27.07

Returns & efficiency

Return on average equity - 5 year average14.47
Net Income/employee - trailing 12 month10,72,664.00
Revenue/employee - most recent fiscal year91,31,542.00
Return on investment - most recent fiscal year11.52
Return on average assets - most recent fiscal year9.69
Receivables turnover - most recent fiscal year5.03
Inventory turnover - most recent fiscal year1.72
Revenue/employee - trailing 12 month90,29,424.00
Return on average assets - 5 year average11.66
Net Income/employee - most recent fiscal year12,54,755.00
Asset turnover - most recent fiscal year0.71
Return on average equity - most recent fiscal year11.82
Return on investment - 5 year average14.07

Price & volume

Market Cap1,12,074.20
52 week Low Date2 Apr 2026
Price - 1 Day % Change−1.14
Relative (S&P500) price percent change - 13 week0.33
Avg trading volume last 10 days1.00
Price - 13 week price percent change−4.84
Price - 52 week price percent change−7.72
Avg Trading Volume Last 3 months22.46
Price - 5 Day % Change−0.17
Price % Change Month To Date−1.81
Relative (S&P500) price percent change - 04 week3.84
52 week High Date23 Oct 2025
Price - 26 week price percent change13.03
PDATE28 Sep 2026
Price - YTD price percent change−8.44
Relative (S&P500) price percent change - 52 week1.99
NPRICE1,383.70
Relative (S&P500) price percent change - 26 week11.75
52 week Low1,165.70
52 week High1,673.00
Beta0.66
Relative (S&P500) price percent change - Year to Date7.22

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹13.00
₹13.00
  • Dividend yield0.94%
  • Payout ratio27.08%
  • 5-year average dividend₹10.50 a share
  • Latest dividend₹13.00 per share · 5 Jun 2026

Corporate calendar

  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • BoardQuarterly Results
Show 13 older events
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • Dividend₹3.00 per share · 150% · Special special dividend
  • BoardAudited Results & Final Dividend
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingPostal Ballot
  • MeetingAnnual General Meeting
  • Dividend₹13.00 per share · 650% · Final dividend
  • MeetingAnnual General Meeting
  • Dividend₹8.50 per share · 425% · Final dividend
  • Dividend₹5.00 per share · 250% · Final dividend
  • Dividend₹5.00 per share · 250% · Final dividend

About Cipla

Biotechnology & Drugs

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Key people

  • Achin GuptaGlobal Chief Executive Officer, Managing Director, Executive Director
  • Ashish AdukiaGlobal Chief Financial Officer
  • Rajendra Kumar ChopraCompliance Officer, Company Secretary

Company facts

  • NSE symbolCIPLA
  • BSE code500087
  • ISININE059A01026
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 50, NIFTY 500
  • Market cap₹1,11,428 Cr
  • Revenue (FY26)₹28,163 Cr
  • Net profit (FY26)₹3,879 Cr

In the News

Recent headlines about Cipla — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Cipla (NSE: CIPLA) last traded at ₹1,379.30 on the NSE, down 0.32% (₹4.43) on the day, as of 29 Sep 2026. The day's range was ₹1,378.00 – ₹1,402.00.

Cipla's 52-week high is ₹1,672.20 (23 Oct 2025) and its 52-week low is ₹1,165.55 (2 Apr 2026). At ₹1,379.30 the share is 17.5% below its high and 18.3% above its low.

Cipla's market capitalisation is ₹1,11,428 Cr (₹1.11L Cr). It is part of the NIFTY 50 index.

Cipla's P/E ratio (trailing 12 months) is 33.06. The sector average is 33.72, so investors pay 2% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹41.70.

Cipla shares are down 7.31% over the last year, down 8.73% so far this year, up 11.03% over 6 months, down 5.14% over 3 months. Over the last year the stock did 1.99% better than the market.

In FY26 (year to Mar 2026), Cipla reported revenue of ₹28,163 Cr (up 2.23% on the year before) and a net profit of ₹3,879 Cr. Earnings per share were ₹48.00.

Yes. Cipla's latest dividend is ₹13.00 per share (650%, final dividend), with an ex-date of 5 Jun 2026. The dividend yield is 0.94%. It has paid 7 dividends in the records shown on this page.

As of Jun 2026: Promoter 29.21%, FII 20.20%, MF 20.56%, Other 30.03%.

Cipla's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Lupin. By market capitalisation it ranks #5 of 6 in this group.

Cipla is almost debt-free — its debt-to-equity ratio is 0.02 and total debt was ₹614 Cr in FY26.